Stock search

Ticker or company name

Zoetis

ZTS · NYSE · Pharmaceuticals

$84,39Up +0,57 (+0,68%)today

Quotes delayed up to 15 min. Updated 16 Nov, 16:00 New York time

Market cap
$32,9 bn
Div. yield
1,6%
Year to date
−33,4%
52 weeks: $68,77$132,49

Ratio score

75/100
Ratio would consider buying

based on 8 metrics as of 16.11.2026 ·

Verdict by our methodology based on current metrics. Not an investment recommendation.

Key metrics

5 ✓ · 2 — · 1 ✕ · 2 n/a · hover over a row or tap it to see the trend

All metrics

MetricValue5-year medianIndustry median
P/E TTM12,433,641,8
Forward P/E12,4—12,4
PEG2,0—3,3
P/S3,48,83,4
EV/EBITDA11,827,324,0
P/FCF13,7—14,0
P/B10,315,88,1

Industry median — across 6 profitable companies in “Pharmaceuticals” in Ratio. Revenue and EPS forecasts for future years and the number of employees are in the paid data plan.

Price chart

Compare with

Choose a stock

Closing prices adjusted for splits and dividends. The S&P 500 index and the intraday chart come later.

Analysts

Ratings, 22 analysts

Buy
9
Hold
13
Sell
0

Beat the EPS forecast in 2 of the last 4 quarters

QuarterEstimateActualSurprise
Q3 20261,531,75Up +14,6%
Q2 20261,871,87Down −0,2%
Q1 20261,631,53Down −6,2%
Q4 20251,421,48Up +4,5%

Price targets and yearly revenue and EPS forecasts are in the paid data plan. These are analysts' opinions, not our verdict.

Financials in charts

MetricQ3'26Q2'26Q1'26Q4'25Q3'25Q2'25Q1'25Q4'24Q3'24Q2'24Q1'24Q4'23
Revenue2,39 bn2,47 bn2,26 bn2,39 bn2,40 bn2,46 bn2,22 bn2,32 bn2,39 bn2,36 bn2,19 bn2,21 bn
EPS1,441,651,421,371,631,611,411,291,501,371,311,14
Margin24,7%28,0%26,6%25,3%30,0%29,2%28,4%25,1%28,6%26,4%27,4%23,7%
FCF717 m538 m291 m732 m805 m308 m438 m689 m784 m370 m455 m699 m

From SEC reports. TTM is the sum of 4 quarters; a year is TTM at the end of the calendar year. Forecast bars are in the paid data plan.

Owners

Ownership structure and major holders (13F filings) are in the paid data plan. They are not part of the score or the traffic light.

Insider trades over 12 months

Over 12 months: purchases $886 367 (3 people), sales $2,54 m.

NameAmountSharesPrice
bisaro paul13 May 2026 · open-market purchase$151 7502 000$75,88
damelio frank a13 May 2026 · open-market purchase$501 3446 650$75,39
mccallister michael b11 May 2026 · open-market purchase$233 2733 000$77,76
peck kristin c17 Feb 2026 · sale$1,38 m10 800$127,55
peck kristin c17 Feb 2026 · sale$1,16 m9 200$126,46

SEC Form 4. Titles and trading plans are not in the data. They are not part of the score or the traffic light.

About the company

Industry
Pharmaceuticals
Exchange
NYSE
Country
US
IPO date
1 Feb 2013

Company description, revenue by segment and region, and the CEO will come later.

Next report
date not announced

An AI summary of the earnings call will come later.

Peers

CompanyPrice
VTRSViatris$20,7436would not consider—+4,3%—
BMYBristol Myers Squibb$62,9381would consider14,0+4,2%18,5%
PFEPfizer$28,8644would watch40,8+1,3%6,3%
MRKMerck & Co.$144,4638would not consider148,5+4,9%3,6%
JNJJohnson & Johnson$282,5544would watch42,9+7,8%16,2%
Compare with peers

Ratio — a score by our methodology, not an investment recommendation.